Salidroside (Phenylethanol Glycoside · Neuroprotective · Adaptogenic)

Compound	Salidroside (Rhodioloside)
Chemical class	Phenylethanol Glycoside (Tyrosol-O-β-D-Glucoside)
CAS	10338-51-9
Primary source	Rhodiola rosea (golden root), multiple Rhodiola spp., Ligustrum lucidum
Key applications	Neuroprotective, anti-fatigue, cardiac protection, adaptogenic
Claim strength	Moderate
Typical form	Rhodiola rosea extract (rosavin 3% + salidroside 1% dual-marker standard)
Buy from Herbuno	Rhodiola Rosea Extract Powder | Golden Root → Rhodiola Root Liquid Extract (Water Soluble) - Rhodiola rosea | Golden Root →

Name origin: Salidroside — also called rhodioloside — is the glucoside of tyrosol (p-hydroxyphenylethanol). The name derives from Salix (willow) where a related compound was identified, though Rhodiola is the primary modern research source. Traditional use: Shares Rhodiola rosea’s traditional use as an adaptogen and anti-fatigue herb in Siberian, Tibetan, and Scandinavian medicine. Salidroside is also present in Cistanche species (desert ginseng) used in TCM for kidney yang tonification and immune support — a separate botanical context from Rhodiola. Research trajectory: Salidroside has its own dedicated research profile distinct from rosavin, with specific evidence for neuroprotection (hypoxia, ischaemia models), cardiac protection, anti-ageing (via AMPK/SIRT1), and anti-fatigue mechanisms. It is considered the more pharmacologically versatile Rhodiola active relative to rosavin. Commercial source: Salidroside is commercially available as a constituent of standardised Rhodiola rosea root extract (3% rosavins + 1% salidroside dual-marker standard) in dry powder and water-soluble liquid formats. See sourcing options below.

---

Evidence for Salidroside Applications

Neuroprotective and hypoxia protection: Salidroside is one of the most studied phytochemicals for high-altitude hypoxia protection — it activates HIF-1α (hypoxia-inducible factor) and improves tissue oxygen utilisation. In ischaemia-reperfusion brain injury models, salidroside reduces infarct volume and neurological deficit. High-altitude expedition supplementation with Rhodiola (salidroside-rich) is an established use in mountaineering communities. Claim strength: Moderate.

Cardiac protection: Salidroside protects cardiomyocytes from ischaemia-reperfusion injury, reduces arrhythmia severity, and activates cardiac AMPK in animal models. Anti-apoptotic and mitochondria-protective mechanisms are well-documented. This application area distinguishes salidroside’s evidence profile from rosavin’s primarily cognitive-fatigue evidence base. Claim strength: Moderate.

Anti-ageing and longevity: Salidroside extends lifespan in model organisms (C. elegans, Drosophila) and activates AMPK/SIRT1 longevity pathways in mammalian cells. It reduces cellular senescence markers and improves mitochondrial biogenesis in aged cells. Human anti-ageing data are limited to observational associations with Rhodiola consumption in Siberian populations with exceptional longevity. Claim strength: Emerging (compelling mechanistic; limited human data).

---

Dosage & Formulator Specification

Clinical dose as part of Rhodiola dual-marker extract: 2–6 mg/day salidroside (at 1% content in a 200–600 mg/day extract dose). For isolated salidroside applications, preclinical effective doses suggest 10–50 mg/day as a working estimate for neuroprotective and adaptogenic effects. Dedicated salidroside isolate is available from specialist suppliers for research formulation contexts.

Salidroside as a tyrosol glucoside is water-soluble (better than rosavin). Absorbed partly intact and partly after gut microbial hydrolysis to tyrosol + glucose. Tyrosol itself has antioxidant and cardiovascular activity (present in olive oil as a native phenylethanol), meaning salidroside serves as both an intact bioactive and a tyrosol prodrug. Stable in standard extract formats.

---

Frequently Asked Questions — Salidroside

Is salidroside from Rhodiola the same as from Cistanche?
Chemically identical — salidroside is salidroside regardless of botanical source. However, Cistanche tubulosa (desert ginseng) extracts standardised to echinacoside and verbascoside also contain salidroside as a co-constituent, in a different phytochemical context from Rhodiola. Cistanche-derived salidroside has less dedicated clinical evidence compared to Rhodiola-derived preparations. For adaptogenic and anti-fatigue positioning, Rhodiola remains the more evidence-supported botanical vehicle.

Does salidroside’s conversion to tyrosol in vivo matter pharmacologically?
Yes — tyrosol itself has antioxidant, anti-inflammatory, and cardiovascular protective activity (documented in the context of olive oil consumption). Gut microbial hydrolysis of salidroside to tyrosol means that part of salidroside’s systemic activity may be mediated by tyrosol. This pharmacokinetic consideration does not diminish salidroside’s intact bioactivity (much is absorbed before hydrolysis occurs) but adds mechanistic context for its cardiovascular effects.

Is salidroside appropriate for high-altitude performance and mountaineering formulations?
Yes — Rhodiola rosea is the most evidence-supported botanical for altitude adaptation in the complement/supplement category. The hypoxia-protective mechanism (HIF-1α activation, improved oxygen utilisation) is mechanistically specific to altitude physiology. Several mountaineering and military performance supplement formulations include Rhodiola specifically for this application. Claimed effects should be positioned as “studied to support healthy oxygen utilisation and physical endurance at altitude” rather than altitude sickness prevention claims (which have drug regulatory implications).

How does salidroside differ from rosavin pharmacologically?
The key mechanistic differences: salidroside has stronger MAO-inhibitory, dopaminergic, and serotonergic activity; stronger cardiac and hypoxia-protective evidence; and stronger anti-ageing (SIRT1/AMPK) mechanistic data. Rosavin has stronger cognitive anti-fatigue clinical evidence (the Swedish RCTs) and adaptogenic Hsp70 induction. Both together represent the full Rhodiola clinical evidence base — which is why dual-marker standardisation is the appropriate quality specification.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery